title: Enhanced affinity bifunctional bisphosphonates for targeted delivery of therapeutic agents to bone.
abstract: Skeletal diseases have a major impact on the worldwide population and economy. Although several therapeutic agents and treatments are available for addressing bone diseases, they are not being fully utilized because of their uptake in nontargeted sites and related side effects. Active targeting with controlled delivery is an ideal approach for treatment of such diseases. Because bisphosphonates are known to have high affinity to bone and are being widely used in treatment of osteoporosis, they are well-suited for drug targeting to bone. In this study, a targeted delivery of therapeutic agent to resorption sites and wound healing sites of bone was explored. Toward this goal, bifunctional hydrazine-bisphosphonates (HBPs), with spacers of various lengths, were synthesized and studied for their enhanced affinity to bone. Crystal growth inhibition studies showed that these HBPs have high affinity to hydroxyapatite, and HBPs with shorter spacers bind more strongly than alendronate to hydroxyapatite. The HBPs did not affect proliferation of MC3T3-E1 preosteoblasts, did not induce apoptosis, and were not cytotoxic at the concentration range tested (10(-6)-10(-4) M). Furthermore, drugs can be linked to the HBPs through a hydrazone linkage that is cleavable at the low pH of bone resorption and wound healing sites, leading to release of the drug. This was demonstrated using hydroxyapatite as a model material of bone and 4-nitrobenzaldehyde as a model drug. This study suggests that these HBPs could be used for targeted delivery of therapeutic agents to bone.
authors.affiliation: Department of Chemistry, University of Kentucky, Lexington, Kentucky 40506-0055, United States.
authors.forename: Jivan N
authors.initials: JN
authors.lastname: Yewle
authors.forename: David A
authors.initials: DA
authors.lastname: Puleo
authors.forename: Leonidas G
authors.initials: LG
authors.lastname: Bachas
mesh_terms: D016475:3T3 Cells; D000818:Animals; D017209:Apoptosis; D001842:Bone and Bones / Q000378:metabolism*; D002460:Cell Line; D003692:Delayed-Action Preparations / Q000737:chemistry* / Q000378:metabolism*; D004164:Diphosphonates / Q000737:chemistry* / Q000378:metabolism*; D006834:Hydrazines / Q000737:chemistry / Q000378:metabolism; D051379:Mice; D010006:Osteoblasts / Q000166:cytology / Q000378:metabolism
chemical_list: D003692:Delayed-Action Preparations; D004164:Diphosphonates; D006834:Hydrazines; C029424:hydrazine
references.citation: Biopolymers. 2010;94(1):60-77
references.pmid: 20091871
references.citation: Annu Rev Pharmacol Toxicol. 1998;38:375-88
references.pmid: 9597160
references.citation: J Org Chem. 2008 Jun 6;73(11):4123-30
references.pmid: 18473440
references.citation: J Med Chem. 2003 Jul 3;46(14):3021-32
references.pmid: 12825941
references.citation: Mol Pharm. 2006 Nov-Dec;3(6):717-25
references.pmid: 17140259
references.citation: Science. 1997 Apr 11;276(5310):270-3
references.pmid: 9092479
references.citation: Bioconjug Chem. 2006 Jul-Aug;17(4):943-9
references.pmid: 16848401
references.citation: Bioconjug Chem. 2009 Oct 21;20(10):1813-5
references.pmid: 19728697
references.citation: J Bone Miner Res. 1996 Oct;11(10):1492-7
references.pmid: 8889849
references.citation: Curr Opin Rheumatol. 2009 Jul;21(4):380-5
references.pmid: 19461517
references.citation: Science. 2001 Jul 6;293(5527):58-9
references.pmid: 11441170
references.citation: J Drug Target. 2006 Jul;14(6):425-35
references.pmid: 17092842
references.citation: J Clin Invest. 1996 Jun 15;97(12):2692-6
references.pmid: 8675678
references.citation: Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6222s-6230s
references.pmid: 17062705
references.citation: Arch Dermatol Res. 2007 Feb;298(9):413-20
references.pmid: 17091276
references.citation: Nat Rev Drug Discov. 2002 Oct;1(10):784-96
references.pmid: 12360256
references.citation: Science. 2000 Sep 1;289(5484):1508-14
references.pmid: 10968781
references.citation: Mol Pharm. 2009 Mar-Apr;6(2):634-40
references.pmid: 19718808
references.citation: J Nucl Med. 2006 Dec;47(12):2042-7
references.pmid: 17138748
references.citation: Nat Biotechnol. 2001 Dec;19(12):1148-54
references.pmid: 11731784
references.citation: Bioconjug Chem. 2007 Sep-Oct;18(5):1375-8
references.pmid: 17705416
references.citation: Curr Med Chem. 2008;15(4):415-21
references.pmid: 18288996
references.citation: Nature. 2003 May 15;423(6937):349-55
references.pmid: 12748654
references.citation: J Med Chem. 2002 May 23;45(11):2338-41
references.pmid: 12014972
references.citation: Bone. 2006 May;38(5):617-27
references.pmid: 16046206
references.citation: Ann Pharm Fr. 2006 Jul;64(4):260-75
references.pmid: 16902390
references.citation: Nature. 1994 Sep 22;371(6495):346-7
references.pmid: 8090205
references.citation: Bioorg Med Chem. 1999 May;7(5):901-19
references.pmid: 10400344
references.citation: Bioconjug Chem. 2010 May 19;21(5):811-5
references.pmid: 20387897
references.citation: Bioconjug Chem. 2008 Jan;19(1):315-21
references.pmid: 18001076
references.citation: Curr Pharm Des. 2002;8(21):1929-44
references.pmid: 12171528
references.citation: Cancer Biother Radiopharm. 2004 Oct;19(5):627-40
references.pmid: 15650456
references.citation: Chem Soc Rev. 2007 Mar;36(3):507-31
references.pmid: 17325789
references.citation: Science. 2000 Sep 1;289(5484):1504-8
references.pmid: 10968780
references.citation: Biomaterials. 2011 Jul;32(19):4450-63
references.pmid: 21429572
references.citation: J Palliat Med. 2009 Nov;12(11):1061-5
references.pmid: 19922007
references.citation: J Control Release. 2001 Jan 29;70(1-2):183-91
references.pmid: 11166418
references.citation: Clin Interv Aging. 2009;4:121-36
references.pmid: 19503775
references.citation: Bioconjug Chem. 2007 Mar-Apr;18(2):363-70
references.pmid: 17309227
references.citation: Nat Clin Pract Endocrinol Metab. 2006 Apr;2(4):211-9; quiz following 238
references.pmid: 16932286
references.citation: J Drug Target. 2006 Jul;14(6):367-74
references.pmid: 17092837
references.citation: Dalton Trans. 2006 Apr 14;(14):1705-11
references.pmid: 16568178
references.citation: J Control Release. 2006 Oct 10;115(2):175-82
references.pmid: 16959360
references.citation: Adv Drug Deliv Rev. 2004 Sep 22;56(11):1529-31
references.pmid: 15350286
references.citation: PLoS One. 2009;4(4):e5233
references.pmid: 19381291
references.citation: Int J Pharm. 2010 Jan 4;383(1-2):116-22
references.pmid: 19748562
references.citation: Drug Des Devel Ther. 2009 Sep 21;3:27-40
references.pmid: 19920919
references.citation: Endocr Rev. 1998 Feb;19(1):80-100
references.pmid: 9494781